Sjogren syndrome (SS) is one of the most underdiagnosed systemic autoimmune diseases in primary care — it has an average diagnostic delay of approximately 6-7 years from first symptoms, largely because xerostomia and xerophthalmia are attributed to medications, ageing, or anxiety without serological investigation. SS affects approximately 0.5-1% of the population, with a female:male ratio of approximately 9:1 and peak onset in the fourth and fifth decades. The most important primary care principle: any patient with both dry mouth AND dry eyes (the sicca complex), particularly a middle-aged woman, should have ANA + anti-Ro (SSA) + anti-La (SSB) requested. Anti-Ro antibodies are present in approximately 70% of primary SS and anti-La in approximately 40%. The extraglandular consequences of untreated SS include: peripheral neuropathy, interstitial lung disease, renal tubular acidosis, and — most importantly — a 5-10-fold increased risk of non-Hodgkin B-cell lymphoma compared to the general population, predominantly affecting the parotid gland and MALT-type.

The anticholinergic burden scoring in polypharmacy is an essential primary care tool for identifying medication-induced xerostomia — the Anticholinergic Cognitive Burden (ACB) scale assigns each anticholinergic medication a score of 1 (mild), 2 (moderate), or 3 (severe). A total ACB score ≥3 is associated with significant anticholinergic effects including xerostomia, constipation, urinary retention, confusion, and impaired cognitive function. Common high-scoring medications: amitriptyline (3), oxybutynin (3), chlorphenamine (3), tolterodine (3), olanzapine (3), paroxetine (3), clozapine (3). Medicines optimisation for dry mouth should include a systematic ACB calculation for every patient on three or more of these drug classes — if ACB total ≥3, consider: switching amitriptyline to nortriptyline (lower anticholinergic burden), switching to a less anticholinergic antihistamine (loratadine = 0), switching oxybutynin to mirabegron (beta-3 agonist — no anticholinergic effect).

The unstimulated whole salivary flow rate (UWSFR) is an objective measure of salivary output that supplements the clinical diagnosis of xerostomia — patients collect all saliva for 15 minutes by allowing it to drip from their lips into a pre-weighed container (unstimulated, no chewing or swallowing), and the result is expressed in mL per minute. Normal range: 0.3-0.5 mL/min. Xerostomia threshold: <0.1 mL/min (severe), 0.1-0.2 mL/min (moderate). In Sjogren syndrome, the UWSFR is typically <0.1 mL/min in established disease. This test is performed in specialist oral medicine or rheumatology clinics — GPs will not routinely perform it, but should be aware that a specialist may report it when assessing Sjogren syndrome or radiation-induced xerostomia. The subjective complaint of dry mouth does not always correlate with objective flow rates — some patients with measurable salivary flow still report significant dryness (possibly due to altered saliva composition rather than just reduced quantity).

IgG4-related disease is an increasingly recognised cause of bilateral salivary and lacrimal gland enlargement (historically termed Mikulicz disease) that is clinically indistinguishable from Sjogren syndrome on examination — both present with bilateral parotid, submandibular, and lacrimal gland swelling with associated sicca symptoms. The distinguishing investigations: IgG4-RD has a markedly elevated serum IgG4 (above 1.35 g/L, often above 4-5 g/L), negative anti-Ro/La antibodies, and characteristic histology (storiform fibrosis + obliterative phlebitis + IgG4+ plasma cell infiltrate). The therapeutic implication is significant: IgG4-RD responds dramatically and rapidly to oral prednisolone (40 mg OD for 4 weeks, then taper) — gland swelling resolves over days to weeks. Sjogren syndrome does not respond to short-course corticosteroids in the same way. A patient with salivary gland disease and negative Sjogren serology should have serum IgG4 checked before labelling as seronegative Sjogren.

Sjogren syndrome lymphoma surveillance is a primary care responsibility that is easily overlooked — the 5-10-fold elevated risk of B-cell lymphoma (predominantly MALT-type arising in salivary glands) in Sjogren syndrome means that GPs monitoring these patients must be alert to the warning signs: rapid unilateral parotid gland enlargement (particularly after previous stable bilateral enlargement), new firm parotid mass, new cervical lymphadenopathy, new B symptoms (fever, night sweats, weight loss), rising LDH or beta-2 microglobulin, and new peripheral blood cytopenias. Any of these features in a Sjogren syndrome patient requires urgent haematology/oncology referral and CT staging. GPs should also be aware that Sjogren syndrome patients on hydroxychloroquine (used for systemic manifestations) may have a lower lymphoma risk — this is one of the proposed mechanisms behind hydroxychloroquine's benefits in Sjogren.

The pilocarpine prescribing decision for xerostomia requires clinical assessment of residual salivary gland function — pilocarpine is a muscarinic receptor agonist that stimulates saliva secretion from acinar cells, but it can only work if there are functional acinar cells remaining. In Sjogren syndrome, some acinar tissue is preserved (especially early in the disease), and pilocarpine is effective — clinical trials show a median increase in unstimulated salivary flow of approximately 0.08-0.12 mL/min and significant patient-reported improvement. In post-radiotherapy xerostomia, efficacy depends on the degree of acinar destruction — with doses above 60 Gy to both parotid glands, pilocarpine provides minimal benefit (no functional tissue to stimulate). The practical prescribing approach: start pilocarpine 5 mg TDS with food (reduces GI side effects), review at 4-6 weeks for objective benefit assessment (has the patient noticed any subjective improvement?), and discontinue if no benefit after 6-8 weeks of adequate dosing.

The Duraphat 2800 ppm fluoride toothpaste prescription by GPs is a primary care tool that is significantly underutilised for xerostomia-related dental protection — at standard care on an NHS prescription form (FP10), Duraphat 2800 ppm (fluoride 2800 mg/kg in standard toothpaste tube) can be prescribed by any GP or dentist. The rationale: saliva normally provides a continuous supply of calcium, phosphate, and fluoride that remineralises tooth enamel throughout the day — in xerostomia, this protective mechanism is absent, and caries can develop rapidly (particularly at the cervical margin, under crown margins, and on root surfaces). High-concentration fluoride toothpaste dramatically increases fluoride uptake into enamel, providing a pharmacological substitute for the mineralising effect of saliva. The patient instruction: apply a pea-sized amount, brush for 2 minutes, spit but do not rinse (leaving the fluoride residue on tooth surfaces maximises uptake). This simple prescribing intervention prevents the cascade of extraction, denture fitting, and denture-related problems that xerostomia can cause.

Acupuncture for radiation-induced xerostomia has accumulated a meaningful evidence base since the landmark NCCAM-sponsored pilot RCT (Braga et al., 2011) showed that 12 weeks of traditional Chinese acupuncture at points including ST36, CV24, and LI4 significantly improved salivary flow and patient-reported xerostomia versus sham acupuncture. A subsequent definitive RCT (Simcock et al., JAMA Oncology 2022) using a pragmatic design in NHS head and neck cancer patients confirmed that 8 weekly sessions of acupuncture produced significantly greater reduction in xerostomia scores compared to standard care alone, with effects maintained at 6-month follow-up. Given the limited pharmacological options for post-radiotherapy xerostomia (pilocarpine often ineffective after complete gland destruction), NHS commissioners should consider acupuncture as a non-pharmacological option for this patient group. GPs can refer to NHS community acupuncture services (where available) or discuss private provision for patients with significant post-radiotherapy xerostomia.

The Sjogren syndrome to lymphoma surveillance responsibility is shared between GP, rheumatology, and haematology — GPs who are reviewing Sjogren patients annually must act on the warning signs of lymphoma: new asymmetric parotid enlargement, persistent lymphadenopathy (particularly cervical), unexplained weight loss, drenching night sweats, rising beta-2 microglobulin or LDH, new cytopenias, or newly detected paraprotein on protein electrophoresis. The EULAR Sjogren syndrome lymphoma risk score (ESSDAI) stratifies risk, but the most actionable principle for GPs is: any of these warning features in a Sjogren patient = same-week rheumatology/haematology referral + CT chest/abdomen/pelvis.